TY - JOUR
T1 - Anti-TNF therapy in Crohn's disease
T2 - A balance between a targeted therapeutic approach and drug-induced immunogenicity
AU - Cuffari, Carmelo
PY - 2007/12/1
Y1 - 2007/12/1
N2 - Evaluation of: Schreiber S, Khaliq-Kareemi M, Laurence IC et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 239–250 (2007). Crohn's disease is a chronic idiopathic inflammatory bowel disorder with no known cure. Patients generally require drug therapy over their lifetime in order to induce and maintain disease remission and an improved quality of life. Although anti-TNF therapies have proven efficacy in the treatment of patients with Crohn's disease, not all patients respond, while others show a loss of efficacy over time on maintenance therapy. The risk for immunogenicity with certain forms of anti-TNF therapy has led to the development of novel biologics, including certolizumab pegol. This paper evaluates the results of a large randomized placebo-controlled trial with certolizumab pegol in the maintenance (26 weeks) of remission in patients with moderate-to-severe Crohn's disease.
AB - Evaluation of: Schreiber S, Khaliq-Kareemi M, Laurence IC et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 239–250 (2007). Crohn's disease is a chronic idiopathic inflammatory bowel disorder with no known cure. Patients generally require drug therapy over their lifetime in order to induce and maintain disease remission and an improved quality of life. Although anti-TNF therapies have proven efficacy in the treatment of patients with Crohn's disease, not all patients respond, while others show a loss of efficacy over time on maintenance therapy. The risk for immunogenicity with certain forms of anti-TNF therapy has led to the development of novel biologics, including certolizumab pegol. This paper evaluates the results of a large randomized placebo-controlled trial with certolizumab pegol in the maintenance (26 weeks) of remission in patients with moderate-to-severe Crohn's disease.
KW - Crohn's disease
KW - immunogenicity
KW - inflammatory bowel disease TNF-α
UR - http://www.scopus.com/inward/record.url?scp=85027916347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027916347&partnerID=8YFLogxK
U2 - 10.1586/17474124.1.2.233
DO - 10.1586/17474124.1.2.233
M3 - Article
AN - SCOPUS:85027916347
SN - 1747-4124
VL - 1
SP - 233
EP - 237
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
IS - 2
ER -